Citations

Clear

3942 citation(s) found for "To, Van".

Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society
Lennep, Jeanine E. Roeters van , Tokgözoğlu, Lâle , Badimón, Lina , Dumanski, Sandra M. , Gulati, Martha , Hess, Connie N. , Holven, Kirsten B. , Kavousi, Maryam , Kayıkçıoğlu, Meral , Lutgens, Esther , Stock, Jane K., Tybjærg‐Hansen, Anne, Benn, Marianne , Roeters van Lennep, Jeanine E , Michos, Erin D , Prescott, Eva , Wermer, Marieke J H , Benn, Marianne , Lutgens, Esther , Kavousi, Maryam , Michos, Erin D.

Mayo Clinic

European Heart Journal | July 26, 2023 | Volume: 44 | Issue: 39 | Pages: 4157-4173

10.1093/eurheartj/ehad472 | PMID 37611089 Get It

Abstract Cardiovascular disease is the leading cause of death in women and men globally, with most due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 years, ASCVD mortality is now increasing, with the fastest relative increase in middle-aged women. Missed or delayed diagnosis and undertreatment do not fully explain this burden of disease. Sex-specific factors, such as hypertensive disorders of pregnancy, premature menopause (especially primary ovarian insufficiency), and polycystic ovary syndrome are also relevant, with good evidence that these are associated with greater cardiovascular risk. This position statement from the European Atherosclerosis Society focuses on these factors, as well as sex-specific effects on lipids, including lipoprotein(a), over the life course in women which impact ASCVD risk. Women are also disproportionately impacted (in relative terms) by diabetes, chronic kidney disease, and auto-immune inflammatory disease. All these effects are compounded by sociocultural components related to gender. This panel stresses the need to identify and treat modifiable cardiovascular risk factors earlier in women, especially for those at risk due to sex-specific conditions, to reduce the unacceptably high burden of ASCVD in women.
Vitamin C Deficiency Deteriorates Bone Microarchitecture and Mineralization in a Sex-Specific Manner in Adult Mice
Blouin, Stéphane , Khani, Farzaneh , Messmer, Phaedra, Roschger, Paul, Hartmann, Markus A. , Wijnen, André J. van , Thaler, Roman , Misof, Barbara M. , van Wijnen, Andre J

Mayo Clinic

Journal of Bone and Mineral Research | July 26, 2023 | Volume: 38 | Issue: 10 | Pages: 1509-1520

10.1002/jbmr.4889 | PMID 37493605 Get It

ABSTRACT Vitamin C (VitC) is essential for bone health, and low VitC serum levels increase the risk for skeletal fractures. If and how VitC affects bone mineralization is unclear. Using micro-computed tomography (μCT), histologic staining, as well as quantitative backscattered electron imaging (qBEI), we assessed the effects of VitC on femoral structure and microarchitecture, bone formation, and bone mineralization density distribution (BMDD) in the VitC incompetent Gulo−/− mouse model and wild-type mice. In particular, VitC-supplemented, 20-week-old mice were compared with age-matched counterparts where dietary VitC intake was excluded from week 15. VitC depletion in Gulo−/− mice severely reduced cortical thickness of the diaphyseal shaft and bone volume around the growth plate (eg, bone volume of the primary spongiosa −43%, p < 0.001). Loss of VitC also diminished the amount of newly formed bone tissue as visualized by histology and calcein labeling of the active mineralization front. BMDD analysis revealed a shift to higher calcium concentrations upon VitC supplementation, including higher average (~10% increase in female VitC deficient mice, p < 0.001) and peak calcium concentrations in the epiphyseal and metaphyseal spongiosa. These findings suggest higher bone tissue age. Importantly, loss of VitC had significantly more pronounced effects in female mice, indicating a higher sensitivity of their skeleton to VitC deficiency. Our results reveal that VitC plays a key role in bone formation rate, which directly affects mineralization. We propose that low VitC levels may contribute to the higher prevalence of bone-degenerative diseases in females and suggest leveraging this vitamin against these conditions. © 2023 American Society for Bone and Mineral Research (ASBMR). Abstract Vitamin C deficiency disrupts bone microarchitecture, as well as bone formation and mineralization in Gulo−/− mice, which emphasizes the importance of this micronutrient for the skeleton. Importantly, the female skeleton is significantly more sensitive to vitamin C deficiency than the male skeleton, indicating sex-specific differences in vitamin C requirements for bone.
Effectiveness of Transcatheter Closure of Patent Foramen Ovale in Clinical Practice
Alkhouli, Mohamad , Houten, Holly K. Van , Yao, Xiaoxi , Holmes, David R. , Van Houten, Holly K , Alkhouli, Mohamad , Yao, Xiaoxi

Mayo Clinic

Journal of the American Heart Association | July 25, 2023 | Volume: 12 | Issue: 15 | Pages: No page available

10.1161/jaha.123.030321 | PMID 37489748 Get It

Background Transcatheter closure of patent foramen ovale (PFO) has reduced the risk of recurrent stroke in patients with cryptogenic strokes in randomized clinical trials. Whether PFO closure in clinical practice is associated with similar benefit remains unknown. Methods and Results We identified patients with PFO and a history of ischemic stroke or transient ischemic attack who were treated with PFO closure or medical therapy in the OptumLabs database. The primary end point was recurrent ischemic stroke or systemic embolization. Secondary outcomes included mortality, all stroke, transient ischemic attack, and major bleeding. A total of 6668 propensity‐matched patients were included (PFO closure n=4111; medical therapy n=2557). The incidence of stroke or systemic embolization per 100 person‐years was 2.38 after PFO cohort and 2.99 with medical therapy (hazard ratio [HR], 0.85 [95% CI, 0.68–1.05], P =0.13). Mortality was lower in the PFO closure cohort (1.78 versus 2.59 per 100 person‐years: HR, 0.69 [95% CI, 0.55–0.87], P =0.002). Falsification end points showed that this difference is unlikely to be completely explained by residual confounders. There were no significant differences between the groups in secondary end points including intracranial hemorrhage and major bleeding except for an increase in nonintracranial hemorrhage bleeding among patients treated with oral anticoagulation (1.42 versus 2.16 per 100 person‐years: HR, 0.69 [95% CI, 0.48–0.99], P =0.043). The main end point was consistent in subanalyses including patients <60 years of age, patients with prior stroke, and those treated after the publication of the positive PFO trials in 2017. Conclusions In contemporary US practice, PFO closure is not associated with lower rates of recurrent ischemic stroke or systemic embolization compared with medical therapy. Potential reasons for this discrepancy warrant further investigation.
Reasons and predictors of non-participation in a personalized digital prehabilitation care trial for patients undergoing elective cardiothoracic surgery
Scheenstra, Bart , Bongers, Bart C. , Broeders, Britney, Imkamp, Maike , Susante, Lieke van , Kietselaer, Bas , Maessen, Jos G. , Hof, Arnoud W.J. van ’t , Kietselaer, Bas L J H , Sardari Nia, Peyman

Mayo Clinic

Interdisciplinary CardioVascular and Thoracic Surgery | July 23, 2023 | Volume: 37 | Issue: 2 | Pages: No page available

10.1093/icvts/ivad123 | PMID 37486278 Get It

Abstract OBJECTIVES Prehabilitation through a digital platform could preoperatively improve the physical and mental fitness of patients undergoing cardiothoracic surgery, thereby improving treatment outcomes. This study aimed to describe the reasons and predictors of non-participation in a personalized digital prehabilitation care trial (Digital Cardiac Counseling randomized controlled trial) for patients undergoing elective cardiothoracic surgery. METHODS Adult patients scheduled for elective cardiothoracic surgery at the Maastricht University Medical Center+ were approached to participate in a digital prehabilitation care trial, in which patients were informed about their care pathway, monitored for symptom progression and screened for preoperative modifiable risk factors. Baseline characteristics of all eligible patients and reasons of non-participation were registered prospectively. Predictors of non-participation were determined using logistic regression. RESULTS Between May 2020 and August 2022, 815 patients were eligible for participation; 421 (52%) did not participate in the personalized digital prehabilitation care trial. Reasons for non-participation were ‘lack of internet access or insufficient digital skills’ (32%), ‘wishing no participation’ (39%) and ‘other reasons’ (30%; e.g. vision or hearing impairments, analphabetism, language barriers). Independent predictors of non-participation were age [odds ratio (OR) 1.024 (1.003–1.046), P = 0.024], socioeconomic status [OR 0.267 (0.133–0.536), P &lt; 0.001], current smoker [OR 1.823 (1.124–2.954), P = 0.015] and EuroSCORE II [OR 1.160 (1.042–1.292), P = 0.007]. CONCLUSIONS Half of the eligible patients did not participate in a personalized digital prehabilitation care trial. Non-participants were vulnerable patients, with a more unfavourable risk profile and more modifiable risk factors, who could potentially benefit the most from prehabilitation.
Temporo-Parietal Extraventricular Approach for Deep Brain Stimulation Targeting the Anterior Nucleus of the Thalamus: Institutional Experience
Parisi, Veronica , Gregg, Nicholas M. , Kerezoudis, Panagiotis , Brinkmann, Benjamin H. , Middlebrooks, Erik H. , Gompel, Jamie J. Van , Alcalá-Zermeño, Juan Luis , Van Gompel, Jamie J , Brinkmann, Benjamin H , Middlebrooks, Erik H , Gregg, Nicholas M , Lundstrom, Brian N. , Worrell, Gregory A. , Grewal, Sanjeet S.

Mayo Clinic

Neurosurgery | July 21, 2023 | Volume: 93 | Issue: 6 | Pages: 1393-1406

10.1227/neu.0000000000002600 | PMID 37477444 Get It

BACKGROUND AND OBJECTIVES: The anterior nucleus of the thalamus (ANT) is a common target for deep brain stimulation (DBS) for drug-resistant epilepsy (DRE). However, the surgical approach to the ANT remains challenging because of its unique anatomy. This study aims to summarize our experience with the posterior temporo-parietal extraventricular (TPEV) approach targeting the ANT for DBS in DRE. METHODS: We performed a retrospective analysis of patients with DRE who underwent ANT-DBS using the TPEV approach between January 2011 and February 2021. Subjects with at least 6-month follow-up were eligible. The final lead position and number of active contacts targeting the anteroventral nucleus (AV) of the ANT were assessed using Lead-DBS. Mean seizure frequency reduction percentage and responder rate (≥50% decrease in seizure frequency) were determined. RESULTS: Thirty-one patients (mean age: 32.9 years; 52% female patients) were included. The mean follow-up period was 27.6 months ± 13.9 (29, 16-36). The mean seizure frequency reduction percentage was 65% ± 26 (75, 50-82). Twenty-six of 31 participants (83%) were responders, P < .001. Two subjects (6%) were seizure-free for at least 6 months at the last evaluation. Antiepileptic drugs dose and/or number decreased in 17/31 subjects (55%). The success rate for placing at least 1 contact at AV was 87% (27/31 patients) bilaterally. The number of active contacts at the AV was significantly greater in the responder group, 3.1 ± 1.3 (3, 2-4) vs 1.8 ± 1.1 (2, 1-2.5); P = .041 with a positive correlation between the number of active contacts and seizure reduction percentage; r = 0.445, R 2 = 0.198, P = .012. CONCLUSION: The TPEV trajectory is a safe and effective approach to target the ANT for DBS. Future studies are needed to compare the clinical outcomes and target accuracy with the standard approaches.
Underrepresented in Medicine Student Perspectives on the Selection of a Summer Research Program
Timothee, Patricia , Douse, Dontre’ M. , O’Byrne, Thomas J., O’Neill, Jessica M., Casper, Jenny J., Stokken, Janalee K., Abel, Kathryn M. Van , Yin, Linda X , Bayan, Semirra L. , Van Abel, Kathryn M , Yin, Linda X.

Mayo Clinic

The Laryngoscope | July 18, 2023 | Volume: 134 | Issue: 2 | Pages: 637-644

10.1002/lary.30843 | PMID 37462294 Get It

ObjectivesMany summer research programs (SRPs) for URiM students exist; however, only a few have been established by otolaryngology programs, who have a unique opportunity to provide a diverse experience. We sought to assess URiM undergraduate student perspectives on the most valuable program features that influence decision‐making and how this might be useful to otolaryngology programs seeking to establish pathway programs.Materials and MethodsAn externally facing REDCap survey composed of 37 questions in scaled, multiple‐choice, and open‐ended form. The survey was delivered to applicants via email over two time periods in April 2021 and February 2022. All survey responses were analyzed using descriptive statistics and categorized according to demographic information, program features, and advertising mechanisms.ResultsSeventy‐one percent of our applicants self‐identified as URiM. Over 60% experienced financial hardship, and 31% experienced educational hardship. The single most important feature when selecting a summer research program (SRP) was access to mentorship followed by clinical shadowing and research opportunities. When program features were aggregated into groups, institutional features were the most important, followed closely by funding features. Finally, students prefer to learn about SRPs through their university, followed by social media, despite many students learning about our program through other means.ConclusionsPaid programs with effective advertising, research, mentoring, and clinical shadowing are highly valued by URiM undergraduate students. Understanding student perspectives is critical for programs aiming to address the “leaky pipeline” while being deliberate in their support of underrepresented students.Level of Evidence5 Laryngoscope, 134:637–644, 2024
Racial disparities in surgical treatment of oropharyngeal cancer: A Surveillance, Epidemiology, and End Results review
Douse, Dontre’ M. , Olawuni, Felicia O., Glasgow, Amy E. , Tasche, Kendall K. , Moore, Eric J. , Abel, Kathryn M. Van , Moore, Eric J , Van Abel, Kathryn M , Douse, Dontre' , Yin, Linda X. , Habermann, Elizabeth B. , Price, Daniel L.

Mayo Clinic

Head & Neck | July 18, 2023 | Volume: 45 | Issue: 9 | Pages: 2313-2322

10.1002/hed.27467 | PMID 37461323 Get It

AbstractObjectivesOropharyngeal squamous cell carcinoma (OPSCC) has been rising. This manuscript looks to explore racial disparities in the surgical management of OPSCC.MethodsA cancer database was queried for patients with OPSCC diagnosed from 2004 to 2017. Univariate and multivariable logistic regressions were used to evaluate associations between patient race/ethnicity, surgical treatment, and reasons for lack of surgery.Results37 306 (74.3%) patients did not undergo surgery, while 12 901 (25.7%) patients did. Non‐Hispanic black (NHB) patients were less likely to undergo surgery than other races (17.9% vs. 26.5%; p < 0.0001). In clinical discussions, the Asian, Native American, Hawaiian, Pacific Islander (ANAHPI), and unknown race group was more likely to directly refuse surgery when recommended (2.5% vs. 1.5%; p = 0.015).ConclusionRacial differences exist in treatment for OPSCC. NHB patients are less likely to actually undergo surgical management for OPSCC, while other patients are more likely to directly “refuse” surgery outright when offered.
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay
Coelho, Teresa , Grogan, Martha , Conceição, Isabel , Kristen, Arnt V. , Wixner, Jonas , González‐Moreno, Juan , Maurer, Mathew S. , García‐Pavía, Pablo , Tournev, Ivailo , González‐Costello, José , Cariou, Eve, Glass, Oliver, Chapman, Doug, Amass, Leslie, investigators, on behalf of the THAOS, Hüsing‐Kabar, Anna, Drachman, Brian, Sekijima, Yoshiki , Jeon, Eun‐Seok , Slosky, David, Hanna, Mazen , Freimer, Miriam , Muñoz-Beamud, Francisco, Mølgaard, Henning, Press, Rayomand , Cirami, Calogero Lino , Plana, Josep Maria Campistol, Inamo, Jocelyn , Quan, Dianna , Dori, Amir , Murali, Srinivas, Živković, Saša , Correia, Edileide de Barros , Nicolau, José Nativi, Tallaj, José , Fernández‐Torrón, Roberto , Polydefkis, Michael , Tauras, James M. , Ventura, Hector, Brunkhorst, Robert, Darstein, Felix , Marburger, Tessa, Mueller, Christopher R. , Cleemput, Johan Van , Parman, Yeşim , Sarswat, N., Warner, Alberta L. , Steidley, D. Eric , Ralph, Jeffrey , Cotts, William, Hoffman, James E. , Rugiero, Marcelo, Misawa, Sonoko , Muñoz-Blanco, José Luís , Dávila, Lucía Galán, Sadeh, Menachem , Luo, Jin, Kyriakides, Theodoros , Wang, Annabel , Dispenzieri, Angela , Conceição, Isabel , Garcia-Pavia, Pablo , Dispenzieri, Angela , Waddington‐Cruz, Márcia , Diemberger, Igor , Maurer, Mathew S , Planté‐Bordeneuve, Violaine , González-Duarte, Alejandra , investigators, on behalf of the THAOS, Barroso, Fábio , Ueda, Mitsuharu , Mazzeo, Anna Teresa , Gentile, Luca , Luigetti, Marco , Adams, David , Nienhuis, Hans L. A. , Emdin, Michele , Miller, Edward J. , Hummel, Scott L. , Witteles, Ronald , Shah, Sanjiv J , Lenihan, Daniel , Azevedo, Olga , Tan, Cheng‐Yin , Fine, Nowell Mark , Tschöpe, Carsten , Obici, Laura , BADELITA, Sorina Nicoleta , Gottlieb, Stephen S. , Oh, Jeeyoung , Mueller, Christopher, Salutto, Valeria , Chao, Chi‐Chao , Kaufmann, Horacio

Mayo Clinic

Amyloid | July 17, 2023 | Volume: 30 | Issue: 4 | Pages: 445-448

10.1080/13506129.2023.2229484 | PMID 37459334 Get It

Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel
Yerushalmi, Rinat , Yablonski‐Peretz, Tamar, Wang, Qin , Bolla, Manjeet K. , Michailidou, Kyriaki , Ahearn, Thomas U. , Andrulis, Irene L. , Antoniou, Antonis C. , Auvinen, Päivi , Freeman, Laura Beane, Beckmann, Matthias W. , Bermisheva, Marina , Bodelón, Clara , Bogdanova, Natalia , Bojesen, Stig E. , Byers, Helen, Camp, Nicola J. , Chang‐Claude, Jenny , Chirlaque, María‐Dolores , Collaborators, NBCS, Collée, Margriet J., Dörk, Thilo , Eccles, Diana , Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, García‐Closas, Montserrat , Goldberg, Mark S. , Guénel, Pascal , Hamann, Ute, He, Wei , Hillemanns, Peter , Hoppe, Reiner , Hopper, John L. , Investigators, ABCTB, Jakovchevska, Simona, John, Esther M. , Johnson, Nichola , Jones, Michael E. , Kristensen, Vessela N. , Kurian, Allison W. , Lambrechts, Diether , Lejbkowicz, Flavio, Lindblom, Annika , Loibl, Sibylle , Lori, Adriana , Mannermaa, Arto, Manoochehri, Mehdi, Mavroudis, Dimitrios, Menon, Usha , Nevelsteen, Ines, Obi, Nadia , Offit, Ken, Plaseska‐Karanfilska, Dijana , Park‐Simon, Tjoung‐Won , Patel, Alpa V. , Rack, Brigitte , Rhenius, Valerie , Romero, Atocha , Schwentner, Lukas , Shah, Mitul , Stone, Jennifer , Taylor, Jack A. , Kolk, Lizet E. van der, Wendt, Camilla, Yang, Xiaohong R. , Zheng, Wei , Pharoah, Paul D.P. , Easton, Douglas F. , Ben-Sachar, Shay, Elefant, Naama , Shamir, Ron , Elkon, Ran , Lambrechts, Diether , Michailidou, Kyriaki , Antoniou, Antonis C , Devilee, Peter , Eccles, Diana , Newman, William G , Radice, Paolo , Elkon, Ran , Dörk, Thilo , Lambrechts, Diether , Hillemanns, Peter , Pharoah, Paul D P , Menon, Usha , Evans, D Gareth , John, Esther M , Jones, Michael E , Lambrechts, Diether , Guénel, Pascal , Romero, Atocha , García-Closas, Montserrat , Bogdanova, Natalia V , Taylor, Jack A , Zheng, Wei , Kurian, Allison W , Stone, Jennifer , Bojesen, Stig E , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Levi, Hagai , Carmi, Shai , Rosset, Saharon , Zick, Aviad , Dennis, Joe , Lush, Michael J. , Anton‐Culver, Hoda , Arndt, Volker , Augustinsson, Annelie , Behrens, Sabine , Brenner, Hermann , Castelao, Jose E. , Chung, Wendy K. , Clarke, Christine L. , Collaborators, NBCS, Collée, Margriet , Colonna, Sarah V. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Daly, Mary Beryl , Devilee, Peter , Dossus, Laure , Eliassen, A. Heather , Eriksson, Mikael , Fletcher, Olivia , Fritschi, Lin , Gabrielson, Marike , Gago-Domínguez, Manuela , García-Sáenz, José Á. , Genkinger, Jeanine M. , Giles, Graham G. , Hall, Per N , Hollestelle, Antoinette , Investigators, ABCTB, Jakubowska, Anna , Jernström, Helena , Vijai, Joseph , Kaaks, Rudolf , Хуснутдинова, Э. К. , Kitahara, Cari M. , Koutros, Stella , Lacey, James V. , Marchand, Loı̈c Le , Lubiński, Jan , Mannermaa, Arto, Mulligan, Anna Marie , Murphy, Rachel A. , Newman, William G. , O’Brien, Katie M. , Olshan, Andrew F. , Olson, Janet E. , Panico, Salvatore , Peterlongo, Paolo , Radice, Paolo , Rennert, Gad , Saloustros, Emmanouil , Sandler, Dale P. , Schmidt, Marjanka K. , Sharma, Priyanka , Simard, Jacques , Southey, Melissa C. , Tapper, William , Teras, Lauren R. , Toland, Amanda Ewart , Troester, Melissa A. , Truong, Thérèse , Weinberg, Clarice R. , Ziogas, Argyrios , Dunning, Alison M.

Mayo Clinic

Journal of Medical Genetics | July 14, 2023 | Volume: 60 | Issue: 12 | Pages: 1186-1197

10.1136/jmg-2023-109185 | PMID 37451831 Get It

Background Polygenic risk score (PRS), calculated based on genome-wide association studies (GWASs), can improve breast cancer (BC) risk assessment. To date, most BC GWASs have been performed in individuals of European (EUR) ancestry, and the generalisation of EUR-based PRS to other populations is a major challenge. In this study, we examined the performance of EUR-based BC PRS models in Ashkenazi Jewish (AJ) women. Methods We generated PRSs based on data on EUR women from the Breast Cancer Association Consortium (BCAC). We tested the performance of the PRSs in a cohort of 2161 AJ women from Israel (1437 cases and 724 controls) from BCAC (BCAC cohort from Israel (BCAC-IL)). In addition, we tested the performance of these EUR-based BC PRSs, as well as the established 313-SNP EUR BC PRS, in an independent cohort of 181 AJ women from Hadassah Medical Center (HMC) in Israel. Results In the BCAC-IL cohort, the highest OR per 1 SD was 1.56 (±0.09). The OR for AJ women at the top 10% of the PRS distribution compared with the middle quintile was 2.10 (±0.24). In the HMC cohort, the OR per 1 SD of the EUR-based PRS that performed best in the BCAC-IL cohort was 1.58±0.27. The OR per 1 SD of the commonly used 313-SNP BC PRS was 1.64 (±0.28). Conclusions Extant EUR GWAS data can be used for generating PRSs that identify AJ women with markedly elevated risk of BC and therefore hold promise for improving BC risk assessment in AJ women.
ENIGMA CHEK2 gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
Stolařová, Lenka , Kleiblová, Petra , Šťastná, Barbora , Janatová, Markéta , Soukupová, Jana , Achatz, Maria Isabel , Ambrosone, Christine B. , Apostolou, Paraskevi , Arun, Banu , Auer, Paul L. , Bertelsen, Birgitte , Japan, Biobank, Kamatani, Yoichiro, Morisaki, Takayuki , Nagai, Akiko , Muto, Kaori , Murakami, Yoshinori , Furukawa, Yoichi , Yamanashi, Yuji , Nakamura, Yusuke , Momozawa, Yukihide , Ohnishi, Yozo, Kubo, Michiaki , Higashiue, Shinichi , Kobayashi, Shuzo , Minami, Shiro, Yamaguhci, Hiroki, Arai, Hajime , Yamaji, Ken , Asai, Satoshi , Fujioka, Tomoaki, Obara, Wataru , Mori, Seijiro, Murayama, Shigeo , Miki, Yoshio , Masumoto, Akihide, Yamada, Akira , Nishizawa, Yasuko, Higashiyama, Masahiko, Kutsumi, Hiromu, Koretsune, Yukihiro , Blok, Marinus J. , Brunet, Joan , Calvello, Mariarosaria , Chen, Fei , Cortesi, Laura , Crujeiras-González, Ana , Černá, Marta , Hovhannisyan, Milena, Jelínková, Sandra , Nehasil, Petr , Macháčková, Eva , Krutilkova, Vera, Tavandzis, Spiros , Cerna, Leona, Chvojka, Štěpán, Koudová, Monika , Puchmajerová, Alena, Novotný, Jan , Veselá, Kamila , Hrušková, Lucie , Michalovska, Renata, Schwetzova, Denisa, Vlčková, Zdeňka, Černá, Monika, Hejnalová, Markéta, Jedlickova, Nikol, Šubrt, Ivan , Zavoral, Tomas, Kosařová, Marcela, Vacínová, Gabriela, Janíková, Mária , Kratochvílová, Romana , Curtisová, Václava , Vrtěl, Radek , Scheinost, Ondřej, Duskova, Petra, Putter, Robin De , Efremidis, Anna , Engel, Christoph , Evans, D. Gareth , Feliubadaló, Lídia , Fuentes-Ríos, Olivia , Gómez, E. , Haiman, Christopher A. , Hansen, Thomas van Overeem , Hodge, James M. , Huang, Hongyan , Ishak, Nur Diana Binte , Iwasaki, Yusuke , Konstantopoulou, Irene , Li, Na , Lindström, Sara , Lori, Adriana , Martinez, Elana, Martins, Alexandra , McInerny, Simone , Montagna, Marco , Mori, Luigi , Nathanson, Katherine L. , Patel, Alpa V. , Poppe, Bruce , Rosseel, Toon , Ruddy, Kathryn J. , Santos, Elizabeth Santana Dos , Vachon, Celine M. , Volk, Alexander E. , Weber‐Lassalle, Nana , Weitzel, Jeffrey N. , Yadav, Siddhartha , Zethoven, Magnus, Zhang, Ze Wen, Vega, Ana , Rossing, Maria , Valle, Jesús Del , Nicolo, Arcangela De , Hahnen, Eric , Ngeow, Joanne , Kleibl, Zdeněk , Chen, Chen , Zemankova, Petra , Stastna, Barbora , Janatova, Marketa , Soukupova, Jana , Achatz, M I , Ambrosone, Christine B , Apostolou, Paraskevi , Arun, Banu , Auer, Paul , Barnard, Mollie , Bertelsen, Birgitte , Blok, Marinus J , Boddicker, Nicholas J , Brunet, Joan , Burnside, Elizabeth S , Calvello, Mariarosaria , Campbell, Ian G , Chan, Sock Hoai , Chen, Fei , Chiang, Jian Bang , Coppa, Anna , Cortesi, Laura , Crujeiras-González, Ana , De Leeneer, Kim , de Putter, Robin , DePersia, Allison , Devereux, Lisa , Domchek, Susan M , Efremidis, Anna , Engel, Christoph , Ernst, Corinna , Evans, D Gareth , Feliubadaló, Lidia , Fostira, Florentia , Fuentes-Ríos, Olivia , Gómez-García, Encarna B , González, Sara , Haiman, Christopher A , Hansen, Thomas van Overeem , Hauke, Jan , Hodge, James M , Hu, Chunling , Huang, Hongyan , Ishak, Nur Diana Binte , Iwasaki, Yusuke , Konstantopoulou, Irene , Kraft, Peter , Lacey, James V. , Lazaro, Conxi , Li, Na , Lim, Weng Khong , Lindstrom, Sara , Lori, Adriana , Martı́nez, Marı́a Elena , Martins, Alexandra , Matsuda, Koichi , Matullo, Giuseppe , McInerny, Simone , Michailidou, Kyriaki , Montagna, Marco , Monteiro, Alvaro N , Mori, Luigi , Nathanson, Katherine L , Neuhausen, Susan L. , Nevanlinna, H , Olson, Janet E , Palmer, Julie R , Pasini, Barbara , Patel, Alpa V , Piane, Maria , Poppe, Bruce , Radice, Paolo , Renieri, Alessandra , Resta, Nicoletta , Richardson, Marcy E , Rosseel, Toon , Ruddy, Kathryn J , Santamariña, Marta , Dos Santos, Elizabeth Santana , Teras, Lauren R , Toland, Amanda Ewart , Trentham-Dietz, Amy , Vachon, Celine M. , Volk, Alexander E , Weber-Lassalle, Nana , Weitzel, Jeffrey N , Wiesmuller, Lisa , Winham, Stacey J , Yadav, Siddhartha , Yannoukakos, Drakoulis , Yao, Song , Zampiga, Valentina , Zethoven, Magnus , Zhang, Ze Wen , Zima, Tomas , Spurdle, Amanda B , Vega, Ana , Rossing, Maria , Del Valle, Jesús , De Nicolo, Arcangela , Hahnen, Eric , Claes, Kathleen B M , Ngeow, Joanne , Momozawa, Yukihide , James, Paul , Couch, Fergus J. , Macurek, Libor , Kleibl, Zdenek , Chen, C , Japan, Biobank, Kamatani, Yoichiro, Mushiroda, Taisei , Tanaka, Toshihiro , Yamaguhci, Hiroki, Okazaki, Yasushi , Takahashi, Yasuo , Nagayama, Satoshi , Yoshiyama, Takashi , Boddicker, Nicholas , Burnside, Elizabeth S. , Campbell, Ian , Borecká, Marianna , Foretová, Lenka , Havránek, Ondřej , Vočka, Michal , Michalovska, Renata, Schwetzova, Denisa, Jedlickova, Nikol, Zavoral, Tomáš, Duskova, Petra, Stránecký, Viktor , Leeneer, Kim De , Domchek, Susan M. , González, Sara , Hauke, Jan , Hu, Chunling , Kraft, Peter , Lázaro, Conxi , Matullo, Giuseppe , Michailidou, Kyriaki , Monteiro, Álvaro N.A. , Nevanlinna, Heli , Olson, Janet E. , Palmer, Julie R. , Pasini, Barbara , Radice, Paolo , Renieri, Alessandra , Santamariña, Marta , Teras, Lauren R. , Trentham‐Dietz, Amy , Wiesmüller, Lisa , Winham, Stacey J. , Yannoukakos, Drakoulis , Yao, Song , Zampiga, Valentina , Spurdle, Amanda B. , Claes, Kathleen , James, Paul A. , Couch, Fergus J.

Mayo Clinic

Clinical Cancer Research | July 14, 2023 | Volume: 29 | Issue: 16 | Pages: 3037-3050

10.1158/1078-0432.ccr-23-0212 | PMID 37449874 Get It

Abstract Purpose: Germline pathogenic variants in CHEK2 confer moderately elevated breast cancer risk (odds ratio, OR ∼ 2.5), qualifying carriers for enhanced breast cancer screening. Besides pathogenic variants, dozens of missense CHEK2 variants of uncertain significance (VUS) have been identified, hampering the clinical utility of germline genetic testing (GGT). Experimental Design: We collected 460 CHEK2 missense VUS identified by the ENIGMA consortium in 15 countries. Their functional characterization was performed using CHEK2-complementation assays quantifying KAP1 phosphorylation and CHK2 autophosphorylation in human RPE1–CHEK2-knockout cells. Concordant results in both functional assays were used to categorize CHEK2 VUS from 12 ENIGMA case–control datasets, including 73,048 female patients with breast cancer and 88,658 ethnicity-matched controls. Results: A total of 430/460 VUS were successfully analyzed, of which 340 (79.1%) were concordant in both functional assays and categorized as functionally impaired (N = 102), functionally intermediate (N = 12), or functionally wild-type (WT)–like (N = 226). We then examined their association with breast cancer risk in the case–control analysis. The OR and 95% CI (confidence intervals) for carriers of functionally impaired, intermediate, and WT-like variants were 2.83 (95% CI, 2.35–3.41), 1.57 (95% CI, 1.41–1.75), and 1.19 (95% CI, 1.08–1.31), respectively. The meta-analysis of population-specific datasets showed similar results. Conclusions: We determined the functional consequences for the majority of CHEK2 missense VUS found in patients with breast cancer (3,660/4,436; 82.5%). Carriers of functionally impaired missense variants accounted for 0.5% of patients with breast cancer and were associated with a moderate risk similar to that of truncating CHEK2 variants. In contrast, 2.2% of all patients with breast cancer carried functionally wild-type/intermediate missense variants with no clinically relevant breast cancer risk in heterozygous carriers.